Videos

Learn more about the Precivity™ blood tests through the experience of a patient.

Learn more about C2N Diagnostics and the development of the Precivity™ blood tests for Alzheimer’s disease.

Question 1
How do biomarkers help in diagnosis and treating Alzheimer’s disease?

Question 2
What sets LC-MS apart from traditional immunoassays in Alzheimer’s disease diagnosis?

Question 3
What are the likely advancements in brain health testing?

Question 4
What’s C2N’s role in Alzheimer’s disease staging innovation?

Question 5
How does C2N improve early Alzheimer’s disease detection?

Question 6
What makes blood biomarkers vital for Alzheimer’s disease prevention trials?

Overview of the PrecivityAD® Test for Individuals

 

Overview of the PrecivityAD® Test for Healthcare Providers

 

KSDK-TV (St. Louis) Story on the PrecivityAD® Test

 

St. Louis-Based C₂N Diagnostics has a Blood Test for Alzheimer’s Disease That’s Now in the Market

C₂N CEO Dr. Joel Braunstein explains in this video from HEC-TV Science & Technology that the company is “really the first group to introduce a blood test to the market to aid in the clinical diagnosis of Alzheimer's disease.”

 

Benefits of Blood Test for Screening Alzheimer’s Disease Years Before Symptoms Begin

HEC-TV reports on the benefits of the PrecivityAD® blood test for aiding in the diagnosis of Alzheimer's disease and why an early diagnosis is helpful.